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ABSTRACT 
 
Skeletal muscle of insulin resistant individuals is characterized by lower fasting lipid 
oxidation and reduced ability to switch between lipid and glucose oxidation. The purpose of 
the present study was to examine if chronic hyperglycemia would impair metabolic switching 
of myotubes. Human myotubes were treated with or without chronic hyperglycemia (20 
mmol/l glucose for 4 days), and metabolism of [
14
C]oleic acid (OA) and [
14
C]glucose was 
studied. Myotubes exposed to chronic hyperglycemia showed a significantly reduced OA 
uptake and oxidation to CO2, whereas acid-soluble metabolites were increased compared to 
normoglycemic cells (5.5 mmol/l glucose). Glucose suppressibility, the ability of acute 
glucose (5 mmol/l) to suppress lipid oxidation, was 50 % in normoglycemic cells and reduced 
to 21 % by hyperglycemia. Adaptability, the capacity to increase lipid oxidation with 
increasing fatty acid availability, was not affected by hyperglycemia. Glucose uptake and 
oxidation were reduced by about 40 % after hyperglycemia, and oxidation of glucose in 
presence of mitochondrial uncouplers showed that net and maximal oxidative capacities were 
significantly reduced. Hyperglycemia also abolished insulin-stimulated glucose uptake. 
Moreover, ATP concentration was reduced by 25 % after hyperglycemia. However, none of 
the measured mitochondrial genes were downregulated nor was mitochondrial DNA content. 
Microarray and real-time RT-PCR showed that no genes were significantly regulated by 
chronic hyperglycemia. Addition of chronic lactate reduced both glucose and OA oxidation to 
the same extent as hyperglycemia. In conclusions, chronic hyperglycemia reduced substrate 
oxidation in skeletal muscle cells and impaired metabolic switching. The effect is most likely 
due to an induced mitochondrial dysfunction. 
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Abbreviations: 
ACC; acetyl-CoA carboxylase, AMPK; AMP-activated protein kinase, ASM; acid soluble 
metabolites, B2M; beta-2 microglobulin, ChREBP; charbohydrate responsive element binding 
protein, CPT; carnitine palmitoyl transferase, CYC; cytochrome C, DAG; diacylglycerol, 
DGAT; acyl-CoA:1.2-diacylglycerol acyltransferase, DOG; deoxyglucose, DNP; 
dinitrophenol, ECM; extracellular matrix, ETS; electron transport system, FCCP; 
carbonylcyanide-4-trifluoromethoxyphenylhydrazone, GAPDH; glyceraldehydes 3-phosphate 
dehydrogenase, HG; hyperglycemia, IMCL; intramyocellular lipids, LCA-CoA; long chain 
fatty acyl-CoA, LMM; linear mixed model,  mtDNA; mitochondrial DNA, ND; NADH-
ubiquinone oxidoreductase, NG; normoglycemia, OA; oleic acid, PDK; pyruvate 
dehydrogenase kinase, SCD; stearoyl-CoA desaturase, SPA; scintillation proximity assay, 
TAG; triacylglycerol, UCP; uncoupling protein. 
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1. INTRODUCTION 
 
Metabolic flexibility is the capacity of the body to switch between lipid oxidation in the 
fasting state to carbohydrate oxidation in the fed state and vice versa, i.e. the capacity to 
adjust fuel consumption according to availability [1]. Insulin resistance and type 2 diabetes 
(T2D) have been associated with impaired ability to switch between lipid and glucose 
oxidation [2-3], and  it has been postulated that this impaired metabolic switching is an 
intrinsic property of skeletal muscle [4]. Ukropcova et al showed that the metabolic 
phenotype of the donor was maintained in myotube cultures after removal of in vivo 
neuroendocrine factors [4]. However, metabolic flexibility in vivo has been shown to improve 
by weight loss [3], indicating that lifestyle factors can affect metabolic flexibility. We recently 
showed that treatment with n-3 fatty acids improved metabolic switching of myotubes [5]. 
Whether exposure to chronic hyperglycemia affects metabolic flexibility of skeletal muscle is 
at present unknown.  
There are numerous reports on the effect of environmental and dietary factors on 
development of intramuscular lipid accumulation and insulin resistance. Skeletal muscle of 
obese and insulin resistant subjects is characterized by increased intramyocellular lipids 
(IMCL) and reduced mitochondrial oxidative capacity [6-7]. We have previously shown that 
myotubes from type 2 diabetic subjects have reduced fatty acid oxidation after culturing in a 
non-diabetic environment, implying a genetic defect [8]. Experiments in rats confirmed that 
there is an inherited connection between oxidative capacity and a diabetic phenotype, as rats 
bred to obtain low aerobic capacity were insulin resistant and displayed a diabetic metabolic 
profile [9]. These animals also expressed reduced level of several proteins involved in 
mitochondrial biogenesis, suggesting a genetic association between mitochondrial dysfunction 
and insulin resistance. Several studies have shown reduced mitochondrial content and/or 
mitochondrial dysfunction in skeletal muscle of T2D subjects [10-12]. There is substantial 
support for the hypothesis that reduced oxidative capacity might be the fundamental cause of 
IMCL accumulation and insulin resistance [11, 13]. However, the possibility that 
mitochondrial dysfunction rather is the consequence of insulin resistance can not be excluded. 
In rat, chronic glucose infusion induced insulin resistance in skeletal muscle 
concurrent with increased triacylglycerol (TAG), malonyl-CoA and long-chain fatty acyl-
CoA (LCA-CoA) levels in muscle [14]. Lipid intermediates, such as fatty acyl-CoA, 
ceramides and diacylglycerol, are linked to muscle insulin resistance both in vivo and in 
several in vitro models [15]. Glucose oversupply has also been associated with a range of 
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metabolic changes, such as increased lactate production [16-17], and it has been shown that 
diabetic and obese patients have increased plasma lactate levels [18-19]. The role of lactate is 
not known, but it is most likely more complex than being a simple waste product of 
metabolism (reviewed in [20-21]). It has been hypothesized that lactate is a signaling 
molecule directing metabolic activity. In muscle, lactate inhibits 6-phosphofructo-1-kinase 
and consequently decreases glucose consumption [22].  
Chronic hyperglycemia (HG) has been shown to contribute to insulin resistance in 
skeletal muscle [23]. The mechanism, however, by which HG induces insulin resistance is not 
clear. We have previously shown that treatment of human myotubes with chronic HG reduced 
acute glucose uptake and glycogen synthesis. This reduction accompanied accumulation of 
TAG in the cells, an increased de novo lipogenesis and increased acyl-CoA:1.2-diacylglycerol 
acyltransferase (DGAT) activity, whereas total cell content of glycogen was unchanged [24] . 
The effect of HG was maximal after 4 days and reversible, at least when it came to glycogen 
synthesis [24]. Exposure of 3T3-L1 adipocytes to HG has been found to induce insulin 
resistance and loss of mitochondrial membrane potential [25]. Moreover, mitochondria 
became smaller and more compact, whereas mitochondrial DNA was unaffected by HG [25], 
indicating that HG can induce mitochondrial dysfunction. Therefore, we hypothesized that 
exposure to chronic HG induces some kind of mitochondrial dysfunction leading to impaired 
metabolic switching of myotubes. 
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2. EXPERIMENTAL 
 
2.1. Materials 
L-glutamine, penicillin/streptomycin (10,000 IE/10 mg/ml), HEPES, amphotericin B, L-
carnitine, sodium L-lactate, dinitrophenol (DNP), carbonylcyanide-4-
trifluoromethoxyphenylhydrazone (FCCP), oligomycin and extracellular matrix (ECM) gel 
were from Sigma (St.Louis, MO, USA). Dulbecco’s Modified Eagle’s Medium low glucose 
(DMEM), DMEM-Glutamax, foetal calf serum (FCS), Dulbecco’s Phosphate Buffered Saline 
(DPBS) and trypsin/EDTA (0.05 %) were from Gibco/Invitrogen (Grand Island, NY, USA). 
Ultroser G was from Pall Corporation (St-Germain-en-Laye Cedex, France) and lactic acid 
was from Apotekproduksjon AS (Oslo, Norway). D-[6-
14
C]glucose (56 mCi/mmol - 2.1 
GBq/mmol), D-[1-14C]glucose (54 mCi/mmol – 2.0 GBq/mmol), D-[14C(U)]glucose (10 
mCi/mmol – 0.37 GBq/mmol), [1-14C]oleic acid (53 mCi/mmol – 2.0 GBq/mmol) and L-
[
14
C(U)]leucine (318 mCi/mmol – 11.766 GBq/mmol) were provided by either by American 
Radiolabeled Chemicals Inc. (St.Louis, MO, USA) or by NEN Radiochemicals, PerkinElmer 
(Boston, MA, USA). Insulin Actrapid  was from Novo Nordisk (Bagsvaerd, Denmark). The 
antibodies against AMPK (#2532), phosphorylated AMPK (Thr172, #2531), ACC (#3662) 
and phosphorylated ACC (Ser79, #3661) were from Cell Signaling Technology (Beverly, 
MA, US). The pyruvate dehydrogenase kinase (PDHK) inhibitor AZD7545 was a kind gift 
from CVGI Research Area, AstraZeneca (Alderley Park, UK). Corning
®
 CellBIND
®
 
microplates were from Corning B.V. Life Sciences (Schipol-Rijk, The Netherlands), 96-well 
UNIFILTER
®
 microplate from Whatman (Middlesex, UK), and 96-well Wallac Isoplates, 
TopSeal for 96-well micoplates and the scintillation liquid Optiphase Supermix was from 
PerkinElmer (Waltham, MA, USA). The ATPlite 1 step kit was from PerkinElmer Life and 
Analytical Sciences (Shelton, CT, USA). Bio-Rad Protein Assay Dye Reagent was from Bio-
Rad Laboratories (NY, USA). Thin layer chromatography (TLC) plates (Silica gel) were from 
Merck (Darmstadt, Germany). The primers for CD36, FAS, SCD-1, ACC, ChREBP, PDK-4, 
CYC1, CPT-1A, CPT-1B, UCP-2 and UCP-3 and the housekeeping genes GAPDH and 36B4 
were provided by Invitrogen (Carlsbad, CA, USA). SYBR green and TaqMan reverse 
transcription kit reagents were obtained from Applied Biosystems (Warrington, UK). Agilent 
Total RNA isolation kit was purchased from Agilent Technologies (Santa Clara, CA, USA).  
Primers and probes for ND1 and B2M and qPCR MasterMix Plus Low ROX were from 
Eurogentec (Seraing, Belgium). Puregene DNA isolation kit was from Gentra Systems, 
Qiagen (Germantown, MD, USA). 
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2.2. Human skeletal muscle cell cultures 
Satellite cells were isolated from the M. obliquus internus abdominis of 8 healthy donors, age 
39.9 (± 2.9) years, body mass index 23.5 (± 1.4) kg/m
2
, fasting glucose 5.3 (± 0.2) mmol/l, 
insulin, plasma lipids and blood pressure within normal range and no family history of 
diabetes. The biopsies were obtained with informed consent and approval by the National 
Committee for Research Ethics, Oslo, Norway. The cells were cultured in DMEM-Glutamax 
(5.5 mmol/l glucose) with 2 % FCS, 2 % Ultroser G, penicillin/streptomycin (P/S) and 
amphotericin B until 70-80 % confluence. Myoblast differentiation to myotubes was then 
induced by changing medium to DMEM-Glutamax (5.5 mmol/l glucose) with 2 % FCS, 34 
pmol/l insulin, P/S and amphotericin B. Experiments were performed after 8 days of 
differentiation, and pre-incubation with hyperglycemia (20 mmol/l glucose) was started after 
4 days.  
 
 
2.3. Substrate oxidation assay 
The muscle cells were cultured on 96-well CellBIND
®
 microplates as described above. 
Growth medium was completely removed before addition of substrates. Substrate,  
[1-
14
C]glucose (37 kBq/ml), [6-
14
C]glucose (37 kBq/ml), [
14
C(U)]glucose (37 kBq/ml) or [1-
14
C]oleic acid (37 kBq/ml), was given in DPBS with 10 mmol/l HEPES and 1 mmol/l L-
carnitine (only added with oleic acid). Oleic acid was bound to BSA at a ratio of 2.5/1. A 96-
well UNIFILTER
®
 microplate was mounted on top of the CellBIND
®
 plate as described 
before [26], and the cells were incubated at 37°C for 4 h. The CO2 trapped in the filter was 
counted by liquid scintillation in a MicroBeta™ Trilux scintillation counter (PerkinElmer). 
The remaining cell-associated radioactivity was also assessed by liquid scintillation, and the 
sum of CO2 and cell-associated radioactivity was considered as total substrate uptake. 
Oxidation of [1-
14
C]oleic acid to acid-soluble metabolites (ASM) was measured by acidic 
precipitation of the incubation media. CO2 production from [1-
14
C]oleic acid was measured in 
the presence or absence of various compounds known to modify mitochondrial function; 
dinitrophenol (DNP 100 µmol/l) and carbonylcyanide-4-trifluoromethoxyphenylhydrazone 
(FCCP 0.6 mmol/l) (both mitochondrial uncouplers), and oligomycin (ATP synthase 
inhibitor, 1 µg/ml). From these experiments we calculated baseline (routine) oxidation (R) 
and uncoupled oxidation with FCCP (E), as well as baseline oxidation in the presence of 
8 
 
oligomycin (L) [27]. The net routine flux control ratio was calculated as netR=(R-L)/E. 
Protein content in each well was determined [28], and the data are presented as CO2/mg 
protein, cell-associated substrate/mg protein or ASM/mg protein. 
 
2.4. Lipid distribution 
Myotubes were incubated with [1-
14
C]oleic acid (18.5 kBq/ml, 0.2 mmol/l) for 4 h before they 
were harvested into ice-cold water, centrifuged (1000 g, 5 min), resuspended in distilled water 
and sonicated. Cell-associated lipids were extracted with chloroform:methanol and separated 
by thin layer chromatography as described by Folch et al. [29].  
 
2.5. RNA isolation and analysis of gene expression by real-time RT-PCR   
Human skeletal muscle cells were washed, trypsinized and pelleted before total RNA was 
isolated using Agilent Total RNA isolation kit (Agilent Technologies, Santa Clara, CA, USA) 
according to the supplier’s protocol.  Total RNA (0.1 µg/µl) was reversely transcribed with 
oligo primers using a PerkinElmer Thermal Cycler 9600 (25 C for 10 min, 37 C for 1 h, 99 C 
for 5 min) and a TaqMan reverse-transcription reagents kit (Applied Biosystems, Warrington, 
UK). Real-time PCR was performed using an ABI PRISM  7000 Detection System (Applied 
Biosystems, Warrington, UK). DNA expression was determined by SYBR
®
 Green, and 
primers were designed using Primer Express
®
 (Applied Biosystems, Warrington, UK) 
(sequences in Table 1). Each target were quantified in triplicates and carried out in a 25 µl 
reaction volume according to the supplier’s protocol. All assays were run for 40 cycles (95 C 
for 12 s followed by 60 C for 60 s). The transcription levels were normalized to the reference 
genes GAPDH and 36B4.  
 
2.6. Microarray  
Total RNA was prepared from primary myotubes from three donors using Agilent Total RNA 
isolation kit according to the supplier’s protocol (Agilent Technologies). RNA was used 
individually and RNA integrity was checked on chip analysis (Agilent 2100 bioanalyzer, 
Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's instructions. 
RNA was judged as suitable for array hybridization only if samples exhibited intact bands 
corresponding to the 18S and 28S ribosomal RNA subunits, and displayed no chromosomal 
peaks or RNA degradation products (RNA Integrity Number > 9.0). cRNA synthesis was 
performed using Illumina TotalPrep RNA Amplification (San Diego, CA, USA) according to 
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the supplier’s protocol. Hybridization, washing, and scanning of Illumina Human-6 Express 
BeadChips version 3 arrays (> 48 000 probes) were according to standard Illumina protocols 
(San Diego, CA, USA). Data extraction and quality control was performed using BeadStudio 
version 3.1.3.0 (Illumina) and the Gene Expression module 3.2.7. Arrays were normalized 
using quantile normalization, and expression estimates were calculated by GC robust 
multiarray average background adjustment. Fold change (FC) was calculated as log2-
transformed expression level after HG treatment divided by log2-transformed expression level 
after NG treatment (control), followed by identification of differentially expressed probe sets 
using Intensity-based moderated t-statistics [30]. P-values were corrected for multiple testing 
by using Benjamini and Hochberg’s false discovery rate (FDR) method [31]. Probe sets that 
satisfied the criterion of FDR < 10 % (q-value < 0.1) and fold-change >1.2 or < -1.2, were 
considered to be significantly regulated. GEO accession number GSE19620. 
 
2.7. Mitochondrial DNA copy measurement 
DNA was isolated from whole cell lysates by PureGene DNA isolation kit (Qiagene, 
Germantown, MD, USA). Quantification of mitochondrial DNA (mtDNA) relative to nuclear 
DNA (nDNA) was done by real-time qPCR with TaqMan probes using a Stratagene 
3000mxp. Primer and probe sequences were taken from He et al [32], Bogacka et al [33] and 
Bai et al [34], and confirmed with Primer3. Each target were quantified in triplicates and 
carried out in a 25 l reaction volume (12.5 µl 2 x qPCR mix (dNTP, HotGoldStar DNA 
polymerase, MgCl2 (5 mmol/l), ROX), 0.75 µl fwd primer (300 nmol/l), 0.75 µl rew primer 
(300 nmol/l), 0.5 µl probe (200 nmol/l), 5 µl template (10 ng), 5.5 µl H2O). All assays were 
run for 95ºC in 10 min followed by 45 cycles of 95 C for 15 s and 60 C for 60 s. The 
threshold cycle number (Ct) was used for calculating the relative copy number (Rc) by 
expressing differences in Ct of the mtDNA and nDNA qPCR: Rc = 2
∆Ct
 [35-36]. 
 
2.8. Immunoblotting 
Aliquots with 20 g cell protein (total cell lysate prepared in Laemmli buffer) were separated 
by SDS-PAGE (10 % resolving gel) and transferred to polyvinylidene difluoride membranes. 
The membranes were immunoblotted with AMPK (1:1000), phospho-AMPK (1:1000), ACC 
(1:1000) and phospho-ACC (1:1000) antibodies (Cell Signaling Technology, Beverly, MA, 
US) over night. Immunoreactive bands were visualized with enhanced chemiluminescence 
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(ECL) (Amersham Biosciences, Buckinghamshire, UK), and quantified with Gel-Pro 
Analyzer (version 2.0) software.  
 
2.9. Intracellular ATP and lactate concentrations 
Intracellular concentration of ATP in NG and HG cells was measured with ATPlite 1step kit 
from PerkinElmer Life and Analytical Sciences (Shelton, CT, USA). Luminescence was 
detected with Victor
3
 Wallac 1420 multilabel counter (PerkinElmer). ATP concentration was 
quantified according to a standard curve and given as M ATP/mg cell protein. DNP (100 
µmol/l) which was added as a control, reduced ATP concentration by 30 %.  
Cell medium lactate concentration was measured with a radiometer ABL 715 blood gas 
analyzer (Diamond Diagnostics, Holliston, MA, USA). Medium from 6 well plates were 
harvested after 48 h and analyzed without dilution.  
 
2.10. Protein synthesis 
The cells were grown in CytoStar-T scintillating microplates and incubated with 
[
14
C(U)]leucine (37 kBq/ml, 0.8 mmol/l) on day 8 after initiated differentiation. Incorporation 
of [
14
C]leucine was followed for 10 h with scintillation proximity assay (SPA) technology. 
Uptake and accumulation of leucine in cells treated with hyperglycemia (20 mmol/l glucose 
for 4 days) were compared to normoglycemic control cells (5.5 mmol/l glucose).  
 
2.11. Statistics 
All data are presented as mean ± SEM. Statistical comparison between different treatments 
was performed by Student’s t-test and linear mixed models (LMM) analysis (SPSS ver. 16.0). 
The parameter of interest was entered as the dependent variable and pretreatment (HG and 
NG) and acute treatments were entered as fixed variables. Differences were considered 
statistically significant at p<0.05. All experiments were performed with at least triplicate 
observations, and replicate experiments are performed on cells from different donors and 
given as n.  
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3. RESULTS 
 
3.1. Effect of acute glucose on oleic acid oxidation  
Simultaneous accumulation and oxidation of oleic acid (OA) was determined in human 
skeletal muscle cells (myotubes) as previously described [26]. The suppressive effect of acute 
addition (4 h during CO2 trapping) of glucose on [1-
14
C]OA oxidation was evident at 0.5 
mmol/l glucose (Fig. 1), and at 5 mmol/l glucose OA oxidation was suppressed by 53 %. OA 
oxidation was not significantly suppressed by acute addition of 5 mmol/l deoxyglucose 
(DOG), 1.43 (± 0.83) nmol/mg protein of CO2 was trapped in absence and 1.07 (± 0.55) 
nmol/mg protein in presence of 5 mmol/l DOG (p=0.31, n=3), indicating that the suppressive 
effect of glucose on OA oxidation is due to some downstream metabolites in the glycolytic 
pathway.  
 
3.2. Effect of chronic hyperglycemia on oleic acid metabolism 
To examine whether chronic hyperglycemia affects the suppressive effect of glucose on OA 
metabolism, myotubes were pretreated with hyperglycemia (HG, 20 mmol/l glucose) for 4 
days and OA (0-300 µmol/l) metabolism was measured in the absence and presence of acute 
glucose (5 mmol/l) (Fig. 2). As shown in Fig.1, acute glucose (5 mmol/l) suppressed OA-
oxidation to CO2 by 50 % in normoglycemic cells (Fig. 2A, p<0.0005 overall effect), whereas 
this suppressive effect of acute glucose was not significant in hyperglycemic cells (Fig. 2B). 
Chronic exposure to HG reduced complete oxidation of OA to CO2 by 47 % compared to 
exposure to NG (Fig. 2A and B, p<0.0005, overall effect), indicating that oxidation was 
already suppressed after chronic HG exposure. Incomplete OA oxidation to acid-soluble 
metabolites (ASM) was however increased by 22 (± 8) % in HG cells compared to NG cells 
(p=0.02, data not shown). ASM consist mainly of tricarboxylic acid cycle metabolites and 
reflect incomplete oxidation of fatty acids. Acute glucose did not suppress ASM production, 
neither in NG nor HG cells (data not shown).   
Cellular uptake of OA in NG cells, assessed as the sum of cell-associated and CO2-
trapped radioactivity, increased with increasing concentrations of OA (20-300 µmol/l) 
(p<0.0005) and in presence of glucose (p<0.0005) (Fig. 2C). HG cells on the other hand 
showed no significantly increased OA uptake with increasing OA concentrations (p=0.12) or 
in presence of glucose (p=0.56) (Fig. 2D), showing a reduced sensitivity towards acute 
glucose after chronic HG exposure. The overall cellular uptake of OA was also significantly 
reduced by 32 % in HG cells (p=0.004). However, myotubes exposed to HG showed 21 % 
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increased incorporation of OA into triacylglycerol compared to NG cells (p=0.02, data not 
shown), in accordance with previous findings [24]. The other lipid classes (free fatty acid, 
diacylglycerol, phospholipids, and cholesterol ester) were not significantly affected by HG 
pretreatment.  
The fraction of OA that was oxidized (CO2/cellular uptake) was independent of OA 
concentration, 4.7 (± 0.5) % in NG cells and 4.4 (± 0.5) % in HG cells in absence of glucose. 
Glucose reduced this fraction significantly in NG cells to 1.5 (± 0.2) % (p<0.0005), whereas 
there was no significant reduction (2.6 (± 1.0) % (p=0.17)) in HG cells. The observed effects 
of HG on metabolism, was not due to hypertonicity as previously shown [24].  
 
3.3. Glucose suppressibility and adaptability in myotubes treated with chronic 
hyperglycemia 
To investigate whether HG affected metabolic switching, the parameters suppressibility and 
adaptability were calculated according to previous definitions [5]. Glucose suppressibility, the 
ability of acutely added glucose to suppress lipid oxidation, was markedly reduced to 21 % in 
HG cells compared to 50 % in NG cells (Fig. 3A) (p=0.03). Adaptability, defined as the 
capacity to increase lipid oxidation upon exposure to increasing fatty acid concentrations, was 
present in both NG and HG cells (p=0.04 overall effect). The adaptability seemed to be 
reduced in cells pretreated with HG, although not significantly (Fig. 3B).   
 
3.4. Effect of oleic acid on glucose metabolism in normoglycemic and hyperglycemic cells 
The effect of hyperglycemia on glucose metabolism was also examined. Glucose uptake, 
assessed as the sum of cell-associated and CO2-trapped radioactivity from [6-
14
C]glucose, was 
reduced by exposure to hyperglycemia for 4 days (Fig. 4A), as reported before using a 
standard deoxyglucose uptake assay [24]. The overall glucose uptake in HG cells was 61 % of 
the amount measured in NG cells (p=0.03).  
To evaluate the effect of fatty acids on glucose metabolism, oleic acid (OA) was added 
to the cell culture media during acute glucose uptake (4 h) in concentrations up to 300 µmol/l. 
Glucose uptake seemed to increase with increasing OA concentrations, although not 
significantly (p=0.06), and there was no difference between NG and HG cells (Fig. 4A).  
Oxidation of glucose to CO2 was reduced by HG to the same degree as glucose uptake, 
to 62 % of control cells (p=0.03, Fig. 4B). There was no significant effect of acute oleic acid 
addition on glucose oxidation. The fraction of glucose that was oxidized (CO2/cellular uptake) 
was constant and not dependent on chronic hyperglycemia or concentration of oleic acid (data 
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not shown). The effect of hyperglycemia on glucose metabolism was confirmed with two 
other isotopes of glucose, [1-
14
C]glucose (data not shown) and [
14
C(U)]glucose (Fig. 5B). 
 
3.5. Effect of chronic hyperglycemia on mitochondrial capacity 
To determine the mitochondrial capacity of myotubes pretreated with NG or HG, complete 
oleic acid oxidation and glucose oxidation to CO2 was measured in presence of the 
mitochondrial uncoupler 2.4-dinitrophenol (DNP). DNP (100 µmol/l) increased OA oxidation 
1.5-fold in both NG and HG cells in absence of glucose (Fig. 5A). In accordance with the 
results in Fig. 2, glucose suppressed OA oxidation by about 50 % in NG cells, and 20 % in 
HG cells. There was no statistically significant difference between NG and HG in maximal 
fatty acid oxidation in presence of DNP. With DNP, acute glucose suppressed OA oxidation 
by 39 % in NG cells and by 24 % in HG cells. Additional experiments on OA oxidation were 
performed to further investigate mitochondrial energy production. By use of compounds 
modifying substrate oxidation and calculating net routine flux control ratio (netR) (see 
Experimental) we observed that 52 % of electron transport system (ETS) capacity was 
activated for ATP production in NG cells, whereas this was decreased to 41 % after HG 
treatment (p=0.04, n=3).  
The maximal capacity to oxidize [
14
C(U)]glucose was strongly compromised in HG 
cells (Fig. 5B) to only 47 % of the capacity seen in NG cells (p<0.001). In presence of DNP, 
the suppressive effect of OA on glucose oxidation (OA suppressibility) was also evident. OA 
suppressibility was significantly lower in HG compared to NG cells (23 % vs. 42 % in HG 
and NG cells, respectively, Fig. 5C).  
 
3.6. Gene regulation by chronic hyperglycemia 
To further elucidate the molecular mechanism behind the effects of hyperglycemia on glucose 
and lipid metabolism, we examined by real-time RT-PCR and microarray analysis, gene 
expression in NG and HG cells. Some of the essential genes involved in carbohydrate 
(ChREBP, PDK-4) and fatty acid metabolism (FAS, SCD-1, ACC) and fatty acid uptake 
(CD36) were examined by real-time RT-PCR (Fig. 6). HG did not affect the gene expression 
level of any of the examined genes. Neither were genes associated with mitochondrial 
function (CPT1, CYC1, UCP-2 and UCP-3) changed (Fig. 6). The gene 36B4 was used as 
reference gene, and similar results were obtained when gene expression were related to the 
reference gene glyceraldehyd-3-phosphate dehydrogenase (GAPDH) (data not shown). 
Microarray analysis of gene expression surprisingly showed that no genes were significantly 
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regulated by 4 days of chronic HG (data not shown, Illumina arrays with > 48 000 probes, 
GSE19620). However, it must be emphasized that cells from only 3 subjects were included in 
these experiments, and that might be too few to detect small changes.  
 
3.7. Mitochondrial DNA, ATP and lactate concentration 
Since mitochondrial capacity seemed to be reduced after chronic HG compared to NG, we 
wanted to examine the mitochondrial content, by measuring mitochondrial DNA, of the 
myotubes. Mitochondrial DNA relative to nuclear DNA was not altered by HG (Fig. 7A). 
However, cells exposed to HG contained 25 % less ATP than NG cells (Fig. 7B, p=0.03).  
To examine whether the HG effect could be explained by an increased production of 
lactate, myotubes were pretreated with sodium lactate (1 or 10 mmol/l) for 1-4 days before 
glucose oxidation was measured (Fig. 8A). The effect of HG on glucose oxidation was 
mimicked by lactate, at 10 mmol/l lactate for 4 days glucose oxidation was reduced by 44 % 
(p=0.03). The effect of lactate on glucose uptake was similar to the effects on oxidation (Fig. 
8B). Preincubation with sodium lactate (10 mmol/l) also reduced OA oxidation to the same 
extent as HG (data not shown). Addition of sodium lactate to the cell media did not change 
pH. For comparison the effect of lactic acid (0.01, 0.1 or 0.2 mmol/l) was examined on 
glucose oxidation and uptake, and a similar effect as of HG and lactate treatments was 
observed (Fig. 8C and D). In this case, pH of the culture medium was reduced to 6.8. The 
calculated concentration of non-dissociated lactic acid in the media was similar after addition 
of lactate and lactic acid. To exclude an effect of acidification, HCl was added in an amount 
that gave the same reduction in pH as lactic acid, but HCl had no effect on glucose oxidation 
(data not shown). Insulin-stimulated glucose uptake was abolished by HG (Fig. 9). Lactate 
seemed to reduce the insulin responses as well, although not significantly (p=0.14). However, 
the lactate concentration in the cell media was only slightly increased in cells exposed to HG 
for 4 days, 4.0 (± 0.6) mmol/l versus 3.7 (± 0.5) mmol/l in media from NG cells (n=5, 
p=0.08). The average pH value in the cell media was similar, 7.2 (± 0.2) in both HG and NG. 
This implied a specific effect of lactate independent of pH. 
Impaired glucose oxidation, reduced ATP concentrations and increased lactate 
production could be explained by a dysfunctional pyruvate dehydrogenase (PDH) complex. 
To test whether HG impaired PDH activity, glucose oxidation was measured after incubation 
with a new PDHK inhibitor, AZD7545 (10-100 nM for 2-4 days). The HG-induced reduction 
of glucose oxidation was not abolished by the PDHK inhibitor. Glucose oxidation was 
reduced by 22 % after chronic HG to 13.8 (± 0.9) nmol CO2/mg protein in cells without 
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PDKH inhibition and by 23 % to 10.6 (± 1.8) nmol CO2/mg protein in myotubes pretreated 
for 4 days with a combination of HG and 100 nM AZD7545 (n=3). The activity of the 
inhibitor was confirmed by an acute stimulatory effect on glucose oxidation. AZD7545 (100 
nM for 4 h) increased glucose oxidation by 45 % in NG cells and by 35 % in HG cells.  
 
3.8. Activation of AMPK 
AMPK is known to be an important energy sensor in cells. The involvement of AMPK in 
HG-treated myotubes was therefore of interest. HG had no effect on either AMPK or ACC 
phosphorylation compared to NG control cells (data not shown). However, pretreatment with 
deoxyglucose (DOG) increased phosphorylation of both AMPK and ACC to the same extent 
in NG and HG cells, showing responses to acute energy depletion. 
 
3.9. Effect of chronic hyperglycemia on protein synthesis 
To explore the effect of HG on cellular viability and energy requirement, protein synthesis 
was assessed as [
14
C(U)]leucine uptake and accumulation, measured by a scintillation 
proximity assay (SPA). Protein synthesis was about 2-fold increased after chronic HG 
(p=0.02 overall effect), indicating that hyperglycemia did not cause a reduced energy 
requirement (Fig. 10). Leucine uptake and accumulation was stimulated by insulin (100 
nmol/l) in both NG and HG cells. After 10 h insulin-stimulated [
14
C(U)]leucine accumulation 
was increased by 35.6 (± 7.4) nmol/mg protein in NG cells and by 24.7 (± 10.2) nmol/mg 
protein in HG cells, showing an impaired relative insulin response on protein synthesis in HG-
treated cells (p=0.04, data not shown). 
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4. DISCUSSION 
 
In the present study we showed that chronic exposure of differentiated human skeletal muscle 
cells (myotubes) to hyperglycemia (HG) significantly reduced both glucose and oleic acid 
oxidation and reduced the suppressive effect of acute glucose on oleic acid oxidation. Glucose 
oxidation in presence of a mitochondrial uncoupler (DNP) was also markedly reduced, and 
the same was cellular ATP concentration. Mitochondrial content, as measured by 
mitochondrial DNA, was unchanged and so was the expression level of several mitochondrial 
genes. Moreover, HG did not affect the expression level of any genes measured by real-time 
RT-PCR or microarray. Addition of lactate to control cells mimicked the effect of HG on 
inducing insulin resistance and reducing substrate oxidation. In addition, lactate concentration 
in cell media was slightly increased after hyperglycemia. These results imply that chronic 
hyperglycemia can induce impaired metabolic switching and reduce substrate oxidation in 
healthy myotubes without changing gene expression.   
Metabolic switching of myotubes, characterized by the parameters suppressibility and 
adaptability, has been suggested to be of intrinsic origin and to correlate with in vivo 
characteristics [4]. However, metabolic switching can also be affected by extrinsic factors, as 
we recently showed that n-3 fatty acids improve metabolic switching of myotubes [5]. In the 
present study, glucose suppressibility (the suppressive effect of acute glucose on oleic acid 
oxidation) was significantly reduced by chronic HG. Adaptability (the capacity to increase 
fatty acid oxidation with increasing fatty acid availability) seemed to be reduced by HG 
exposure, although not significantly. This induced impairment of metabolic switching was not 
observed in the opposite situation; oleic acid suppressibility of glucose oxidation at baseline 
conditions. However, in presence of DNP, at maximal mitochondrial electron transport 
system (ETS) capacity, a suppressive effect of oleic acid on glucose oxidation was evident 
after both NG and chronic HG pretreatment of the cells, although significantly lower after 
HG. A possible explanation could be that glycolytic metabolism is preferred in these cells, 
and that a substrate competition was evident only at maximum flux through the ETS caused 
by DNP.  
The acute glucose suppression of lipid oxidation has similarities with the switch from 
fatty acid to carbohydrate oxidation in the postprandial phase and at high intensity exercise. 
The mechanism behind this substrate switch is not known, but the suppressive effect on CO2 
but not on ASM indicates an effect downstream of fatty acid -oxidation. The mechanism is 
probably due to a mitochondrial competition between carbohydrates and fatty acids. This 
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could be mediated by malonyl-CoA inhibiting CPT1 and thereby entry and oxidation of fatty 
acids in mitochondria [37-38]. Another explanation focus on the ETS, and is based on that 
catabolism of carbohydrates produces redox equivalents (NADH) feeding electrons into 
complex I, whereas catabolism of fatty acids produces redox equivalents feeding electrons 
into both complex I and II. Substrate competition at ETS level could possibly be explained by 
differences in relative activity of the complexes and in feedback control on PDH and β-
oxidation by redox state [39]. Our results on substrate oxidation in presence of DNP showed 
that maximal oxidation capacity of glucose, but not OA, was compromised by HG, suggesting 
a defect at the complex I level or upstream. Measurements of mitochondrial function using 
OA as substrate further revealed that 21 % less of ETS capacity was activated for ATP 
production after HG treatment. 
The present results indicate that chronic exposure of myotubes to high glucose 
concentration impairs mitochondrial function. Complete oxidation of glucose and oleic acid to 
carbondioxide was reduced. Incomplete oxidation of oleic acid, i.e. production of acid-soluble 
metabolites (ASM), was increased, as was oleic acid distribution into intracellular 
triacylglycerol (TAG), in accordance with previous findings [24]. The increased storage of 
oleic acid as TAG could partly explain why HG suppresses oleic acid oxidation. Decreased 
complete oxidation in combination with increased incomplete oxidation of fatty acids as 
observed after chronic HG exposure has also been reported to occur in myotubes from obese 
type 2 diabetic individuals [40]. Moreover, an imbalance between β-oxidation and TCA cycle 
or electron transport chain activity has been suggested to lead to increased incomplete fatty 
acid oxidation and accumulation of lipid-derived metabolites in the mitochondria, further 
resulting in mitochondrial stress and development of skeletal muscle insulin resistance [41-
43]. Thus, the observed impaired substrate oxidation might be due to an affected step 
somewhere in the TCA cycle or electron transport chain machinery, leading to accumulation 
of lipid-derived metabolites in the mitochondria and possibly impaired metabolic switching.  
Glycolytic products such as lactate and pyruvate might play a regulatory role in the 
mechanism behind metabolic switching. The effect of HG on glucose uptake and oxidation 
was mimicked by extracellular addition of lactate. The activity of CPT-1 is strongly pH-
dependent, and could possibly be inhibited by lactate [44]. However, in the present study 
addition of lactate also inhibited glucose oxidation and this effect was rather specific since 
acidification by HCl did not decrease glucose oxidation. In addition, lactate did not change 
the pH of the cell culture medium. A specific effect of lactate is also supported by the lactic 
acid experiments. Recently, lactate was found to be the ligand for the orphan G-protein-
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coupled receptor GPR81, and it was shown that lactate regulated adipocyte lipolysis through 
this receptor [45]. In muscle lactate is known to decrease glucose consumption and glycolytic 
flux [46].  Although lactate concentration was only slightly increased in cell media of 
myotubes exposed to chronic HG, it suggests that glucose oversupply pushes the glycolytic 
pathway. Intramyocellular lactate concentration was not measured, but could be increased to a 
greater extent. Possibly, recycling of lactate back into glucose could also explain the reduced 
ATP level, and there exist evidence that this futile cycle is active in myotubes [47]. An 
increased lactate production can be caused by increased lactate dehydrogenase activity, 
reduced activity of pyruvate dehydrogenase (PDH) or lack of acetyl CoA. PDH activity is 
controlled by PDH kinase, and if HG increased PDHK activity and thereby reduced PDH 
activity, an inhibitor of PDHK might then relieve the HG effect. The PDHK inhibitor, 
AZD7545, however showed no effect on the reduced glucose oxidation caused by HG. 
Changed PDH activity by any other mechanism can however not be excluded by these 
experiments. Whether the effect of HG is mediated by lactate is uncertain, and should be more 
thoroughly studied. Any effect of lactate or chronic HG on lipolysis in muscle is not known 
and should also be examined. The present finding of increased storage of oleic acid as 
triacylglycerol (TAG), together with previous observations of increased TAG content in 
myotubes treated with chronic hyperglycemia [24] could imply that lipolysis might be 
affected. In theory, glucose oversupply could also possibly increase cell glycogen content and 
thereby favor utilization of glucose derived from stored glycogen and suppress lipid 
oxidation. However, based on previous results we have no reasons to believe that glycogen 
content is increased after HG in absence of insulin [24].   
The reduced mitochondrial capacity could not be explained by altered gene expression 
or by a decreased number of mitochondria. In fact, the protein synthesis experiments showed 
that the cells in energy surplus were more actively accumulating leucine, indicating high 
metabolic activity. This is in accordance with a previous study showing increased protein 
synthesis in hyperglycemic diabetic patients [48]. Resistance towards insulin-stimulated 
protein anabolism has also been reported in type 2 diabetics [49]. Insulin-stimulated protein 
synthesis was reduced in cells pretreated with HG confirming insulin resistance, which was 
also observed on glucose uptake. Why the muscle cells then turn down energy production 
(ATP) and increases energy storage is not known. Of course, other energy demanding 
processes than protein synthesis could be affected by HG, such as calcium recycling or other 
membrane-associated pumping activities.  
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Surprisingly, no genes were found to be significantly regulated by chronic HG. These 
results suggest that the metabolic effects of HG might be mediated by altered protein 
activities caused by some form of post-translational modification, e.g. phosphorylations, 
glycations or acetylations. Previously, we have reported that neither phosphorylation of PKB 
[24] nor ERK [50] is affected by chronic HG. Glucose infusion to rats has been shown to 
induce increased PKC activation [51] and to reduce phosphorylation and activation of AMPK, 
an important sensor of energy status and regulator of energy metabolism in cells [52]. In the 
present study, chronic HG did not change phosphorylation of AMPK or its substrate ACC. 
These data suggest that although energy uptake and oxidation is reduced, the cells are in an 
energy neutral state. Protein expression and activity of diacylglycerol kinase  has been 
shown to be decreased in type 2 diabetic subjects and normalized upon correction of 
hyperglycemia [53]. This kinase is thought to be involved in the metabolic switch between 
lipid and glucose metabolism and might play a role in the metabolic inflexibility seen in type 
2 diabetes. Other enzymatic changes and protein modifications by HG such as glycosylations 
or glycations can not be excluded and are currently under investigation.  
In conclusion, chronic hyperglycemia impairs substrate oxidation in skeletal muscle 
cells and reduces the metabolic switching of the cells. This shows that hyperglycemia can 
induce a diabetic-resembling phenotype in former healthy cells. The effect is most likely due 
to an induced mitochondrial dysfunction or post-translational modifications. 
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Figure legends 
 
Figure 1 
Suppression of oleic acid oxidation by acute glucose. Myotubes were incubated with  
[1-
14
C]oleic acid (OA) (37 kBq/ml, 100 µmol/l) for 4 h in presence of 0, 0.1, 0.5, 1, 2 or 5 
mmol/l glucose. CO2 was trapped in a filter and counted by liquid scintillation as described in 
Experimental. Complete oleic acid oxidation to CO2 is given as mean ± SEM (n=5). 
 
Figure 2 
Oleic acid metabolism in normoglycemic (NG) and hyperglycemic (HG) cells in absence and 
presence of acute glucose (5 mmol/l). Myotubes were pretreated with 5.5 mmol/l glucose 
(NG) or 20 mmol/l glucose (HG) for 4 days before they were incubated with [1-
14
C]oleic acid 
(OA) (37 kBq/ml, 20-300 µmol/l) for 4 h in absence or presence of acute glucose (5 mmol/l). 
CO2 (A, B) was trapped in a filter and counted by liquid scintillation as described in Figure 1. 
Uptake of OA was assessed as the sum of oxidized OA (trapped CO2) and remaining cell-
associated radioactivity (C, D). Data are given as mean ± SEM (n=3-5). 
 
Figure 3 
Suppressibility (A) and adaptability (B) of oleic acid (OA) oxidation in NG and HG cells. 
Suppressibility was calculated as [1-(OA oxidation (100 µmol/l) in presence of 5 mmol/l 
glucose/OA oxidation at 0 mmol/l glucose)]*100 %. Adaptability was calculated as fold 
increase in OA oxidation from 20 µmol/l OA, here 0 mmol/l and 5 mmol/l glucose are 
merged. These data were calculated from the results in Figure 2. 
*
p<0.05 vs. NG. 
 
Figure 4 
Glucose metabolism at increasing oleic acid concentrations in normoglycemic (NG) and 
hyperglycemic (HG) cells. Myotubes were pretreated with 5.5 mmol/l glucose (NG) or 20 
mmol/l glucose (HG) for 4 days before incubation with [6-
14
C]glucose (37 kBq/ml, 5 mmol/l) 
for 4 h in presence of 0-300 µmol/l oleic acid during CO2 trapping. Glucose uptake assessed 
as the sum of cell-associated glucose and trapped CO2 (A) and CO2 production from glucose 
(B) were assessed as described in Experimetal. Data are given as mean ± SEM (n=3). 
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Figure 5 
Oxidation of oleic acid and glucose in presence of the mitochondrial uncoupler 2.4-
dinitrophenol (DNP). Myotubes were pretreated with 5.5 mmol/l glucose (NG) or 20 mmol/l 
glucose (HG) for 4 days before they were incubated with radiolabeled substrates in the 
absence or presence of DNP (100 µmol/l) for 4 h. (A) [1-
14
C]oleic acid (OA) (37 kBq/ml, 100 
µmol/l) in absence or presence of acute glucose (5 mmol/l) and (B) [
14
C(U)]glucose (37 
kBq/ml) in absence or presence of acute OA (100 µmol/l). (C) Oleic acid suppressibility of 
glucose oxidation was calculated as [1-(glucose oxidation in presence of 100 µmol/l 
OA/glucose oxidation without OA added] *100 %. Data are given as mean (± SEM) (n=4).  
*
p<0.05 vs. basal oxidation without acute glucose and without DNP, 
§
 p<0.05 vs. basal 
oxidation without acute OA and without DNP, 
¤
 p<0.05 vs. NG, 
# 
 p<0.05 vs. NG + DNP.  
 
Figure 6 
Gene expression in myotubes after pretreatment with hyperglycemia (HG) for 4 days relative 
to normoglycemic (NG) cells. Data are given as mean ± SEM (n=4). Expression of the fatty 
acid transporter CD36, fatty acid synthase (FAS), stearoyl-CoA desaturase (SCD-1), acetyl 
CoA carboxylase (ACC), carbohydrate responsive element binding protein (ChREBP), 
cytochrome C (CYC1), carnitine palmitoyltransferase (CPT-1A, -1B), pyruvate 
dehydrogenase kinase (PDK-4) and uncoupling proteins (UCP-2, -3) were studied relative to 
the reference gene 36B4 by real-time PCR as described in Experimental.  
 
Figure 7 
Mitochondrial DNA (A) and ATP concentration (B) in human myotubes. The myotubes were 
grown in normoglycemic medium (NG) or in medium containing 20 mmol/l glucose (HG) for 
4 days before mitochondrial DNA (mtDNA) relative to nuclear DNA (nDNA) was measured 
by real-time PCR, and ATP concentration was measured with an ATPlite 1step kit as 
described in Experimental. Data are given as mean (± SEM) (n=5-7). 
*
 p<0.05 vs. NG. 
 
Figure 8 
Effect of sodium lactate and lactic acid on glucose oxidation and uptake. Myotubes were 
preincubated with sodium lactate (1 and 10 mmol/l) (A, B) or lactic acid (10-200 µmol/l) (C, 
D) for 4 days, before CO2 production from [
14
C(U)]glucose (37 kBq/ml, 5 mmol/l) was 
measured for 4 h. Glucose uptake was assessed as the sum of cell-associated glucose and 
trapped CO2. Data are given as mean (± SEM) (n=4). 
*
 p<0.05 vs. NG.  
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Figure 9   
Insulin-stimulated glucose uptake in myotubes. Myotubes were preincubated with 
normoglycemia (5.5 mmol/l glucose, NG), hyperglycemia (20 mmol/l glucose, HG), sodium 
lactate (10 mmol/l) or lactic acid (0.01 mmol/l) for 4 days, before insulin-stimulated (100 
nmol/l) glucose uptake was measured. CO2 production from [
14
C(U)]glucose (37 kBq/ml, 5 
mmol/l) was measured for 4 h, and glucose uptake was assessed as the sum of cell-associated 
glucose and trapped CO2. Insulin-stimulated glucose uptake is given as % of basal (glucose 
uptake in absence of insulin). Data are given as mean (± SEM) (n=4). 
*
 p<0.05 vs. NG.  
 
Figure 10 
Protein synthesis in normoglycemic (NG) and hyperglycemic (HG) myotubes. The cells were 
grown in CytoStar-T scintillating microplates and incubated with [
14
C(U)]leucine (37 kBq/ml, 
0.8 mmol/l) as described in Experimental.  Incorporation of [
14
C]leucine was followed for 10 
h with scintillation proximity assay (SPA) technology. Data are given as mean ± SEM (n=3). 
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Table 1 
Primer sequences 
Gene Acc.no. Primer 
GAPDH NM_002046 Forward: TGCACCACCAACTGCTTAGC 
Reverse: GGCATGGACTGTGGTCATGAG 
36B4 M17885 Forward: CCATTCTATCATCAACGGGTACAA 
Reverse: AGCAAGTGGGAAGGTGTAATCC 
CD36 L06850 Forward: AGTCACTGCGACATGATTAATGGT 
Reverse: CTGCAATACCTGGCTTTTCTCAA 
FAS U26644 Forward: GAACTCCTTGGCGGAAGAGA 
Reverse: GTTCTGAGAAAGGTCGAATTTGC 
SCD-1 AB032261 Forward: CTCCCCTGCCACACTGATG 
Reverse: GAGCGCTTGGCTTCTCATG 
ACC1 U10822 Forward: AGAATTCACCCAGCAAAATAAAGCTA 
Reverse: CTCCGATCCACCTCATAGTTGAC 
ChREBP NM_032951 Forward: CGGCATTGAGCTCCTCAATC 
Reverse: GCAGAAGACAGCTGAGTACATCCTTA 
CYC1 NM_001916             Forward: CTGCCAACAACGGAGCATT 
Reverse: CGTGAGCAGGGAGAAGACGTA 
CPT-1B NM_004377 Forward: GAGGCCTCAATGACCAGAATGT 
Reverse: GTGGACTCGCTGGTACAGGAA 
CPT-1A NM_001876 Forward: TGCTTTACAGGCGCAAACTG 
Reverse: TGGAATCGTGGATCCCAAA 
PDK-4 BC040239 Forward: TTTCCAGACCAACCAATTCACA 
Reverse: TGCCCGCATTGCATTCTTA 
UCP-2 AF019409.1 Forward: CCTGCGGCTCGGACACATA 
Reverse: GGGGCACCTTTAATCAGCAACA 
UCP-3 AF050113 Forward: AGGACCTTTGCCCAACATCATG 
Reverse: AGTCCAGCAGCTTCTCCTTGAG 
ND1  Forward: CCCTAAAACCCGCCACATCT 
Reverse: GAGCGATGGTGAGAGCTAAGGT 
B2M  Forward: TGCTGTCTCCATGTTTGATGTATCT 
Reverse: TCTCTGCTCCCCACCTCTAAGT 
 
ND1 probe: FAM-CCATCACCCTCTACATCACCGCC-BHQ 
B2M probe: HEX-TTGCTCCACAGGTAGCTCTAGGAGG-BHQ 
 
